Objective: The genetic diversity parameters for gazelle populations sampled in Turkey were estimated to assess the effects of captive breeding on the populations’ gene pools and effective population sizes. Materials and Methods: Four individuals from a recently discovered Gazella gazella population in Hatay and two captive gazelle populations were sampled (the Kızılkuyu State Farm (n=48) and the Erikçe State Farm (n=25)) and analyzed using nuclear DNA, mtDNA and Y-chromosome markers. Results: The mtDNA cyt-b partial sequence analysis assigned the Erikçe and Kızılkuyu samples to Gazella marica. The structure analysis differentiated significantly between them, and revealed samples originating from wild population. Both, the Y-chromosome INRA126 locus sequences of Gazella gazella and Gazella marica males and the mtDNA partial cyt-b region RFLP analysis from all the samples distinguished the two gazelle species from each other. Based on microsatellites, the estimated effective population sizes were 9.7, 8.9 and 6.4 for the Kızılkuyu, Erikçe and Hatay populations, respectively. When the Kızılkuyu and Erikçe populations (where severe inbreeding depressions seems to be occurring already) were pooled, the estimated Ne was 24.5. All these estimates were too small for the sustainability of either individual or pooled populations in the wild or even in captivity. Conclusion: The markers used in the study provided information on two of the gazelle species (Gazella marica, and Gazella gazella): their species identity, degree of divergences, effective population sizes and the presence of admixture within the populations. These results turned out to be invaluable in terms of their contribution to future studies for the conservation of these species.
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
DOI : 10.3906/biy-2005-91
Sayi :44 issue :3 Sayfa :203-214